Did you know Urology Center of Columbus offers Sacral Neuromodulation as a proven treatment option for bladder control and bowel control? More than 150,000 patients worldwide have received Sacral Neuromodulation for bladder control and bowel control.
Sacral Neuromodulation is delivered via the InterStim system. This implantable system sends electrical pulses to an area near the sacral nerve to modulate the neural activity that influences the behavior of the pelvic floor, lower urinary track, urinary and anal sphincters, and colon. Unlike oral medications that target the muscular component of bladder control, Sacral Neuromodulation offers control of symptoms through direct modulation of the nerve activity.
A distinct advantage of Sacral Neuromodulation is that it is tested for potential success prior to moving on to long-term therapy. The evaluation gives patients and physicians an opportunity to find out in as few as 3 to 7 days whether adequate symptom reduction is achieved.
Patients who may benefit from Sacral Neuromodulation include those who have failed or could not benefit from more conservative treatments for one or more of the following conditions:
- Overactive bladder (OAB)
- Urge incontinence
- Non-obstructive urinary retention
- Chronic fecal incontinence
Both men and women are affected by these conditions.
More than 37 million people in the United States – 1 in 6 adults – suffer from OAB.
Many symptomatic patients will not present to their provider for treatment3-5 because they see symptoms as a nuisance or as an embarrassment.
Instead of seeking help, many people with OAB adjust their habits and lifestyle to accommodate the management of symptoms and may adopt such coping mechanisms as restricting fluids and urinating to a timed schedule or at the first sensation of urgency.
As noted in a recent study, of those women who did discuss OAB symptoms with a health care provider, more than half waited at least 1 year to request treatment. The study also found that many health care providers do not screen for OAB. Most women expressed dissatisfaction with currently available OAB treatments and their side effects.